A phase II study of risk-adapted intravenous melphalan in patients with AL amyloidosis

Br J Haematol. 2012 Jun;157(6):766-9. doi: 10.1111/j.1365-2141.2012.09080.x. Epub 2012 Mar 6.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Amyloidosis / drug therapy*
  • Amyloidosis / mortality
  • Antineoplastic Agents, Alkylating / administration & dosage*
  • Antineoplastic Agents, Alkylating / adverse effects
  • Female
  • Humans
  • Melphalan / administration & dosage*
  • Melphalan / adverse effects
  • Middle Aged

Substances

  • Antineoplastic Agents, Alkylating
  • Melphalan